← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Antineoplastic cell and gene therapy
tabelecleucel
L01XL09
Forms & Strengths
- Infused cells, 1-2 million cells/kg
- Frozen, leukapheresed cells
Adult Dosing
- Recommended dose: 1-2 million cells/kg
- Administer over 1-5 minutes after thawing
Pediatric Dosing
- Safety and efficacy not established in < 1 year old
- 1-2 million cells/kg, administer similarly to adults
Indications
- Multicentric Castleman's disease in HIV-infected and HIV-negative patients
- Relapsed or refractory after initial therapy
Mechanism of Action
- Specific T-cell immunotherapy targeting HIV-1 Tat protein
- Innate and adaptive cellular immune responses enhancement
Contraindications
- Severe, uncontrolled infections
- Severe allergic reactions to prior infusions
Adverse Reactions
- Pyrexia, asthenia, and chills
- Hypersensitivity reactions possible
Drug Interactions
- Immunosuppressive drugs: may decrease the effectiveness
- Live vaccines: may increase infection risk
Curated Content: Needs Vetting Before Put to Clinical Use